NF-κB-inducing kinase maintains T cell metabolic fitness in antitumor immunity.
Animals
CD8-Positive T-Lymphocytes
/ enzymology
Cell Line, Tumor
Colonic Neoplasms
/ enzymology
Cytotoxicity, Immunologic
Energy Metabolism
Enzyme Stability
Female
Glucosephosphate Dehydrogenase
/ metabolism
Glycolysis
Hexokinase
/ genetics
Immunotherapy, Adoptive
Lymphocyte Activation
Lymphocytes, Tumor-Infiltrating
/ enzymology
Male
Melanoma, Experimental
/ enzymology
Mice, Inbred C57BL
Mice, Knockout
NADP
/ metabolism
Phenotype
Protein Serine-Threonine Kinases
/ deficiency
Reactive Oxygen Species
/ metabolism
Signal Transduction
Tumor Microenvironment
NF-kappaB-Inducing Kinase
Journal
Nature immunology
ISSN: 1529-2916
Titre abrégé: Nat Immunol
Pays: United States
ID NLM: 100941354
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
07
10
2019
accepted:
29
10
2020
pubmed:
6
1
2021
medline:
7
4
2021
entrez:
5
1
2021
Statut:
ppublish
Résumé
Metabolic reprograming toward aerobic glycolysis is a pivotal mechanism shaping immune responses. Here we show that deficiency in NF-κB-inducing kinase (NIK) impairs glycolysis induction, rendering CD8
Identifiants
pubmed: 33398181
doi: 10.1038/s41590-020-00829-6
pii: 10.1038/s41590-020-00829-6
pmc: PMC7855506
mid: NIHMS1642142
doi:
Substances chimiques
Reactive Oxygen Species
0
NADP
53-59-8
Glucosephosphate Dehydrogenase
EC 1.1.1.49
Hexokinase
EC 2.7.1.1
hexokinase 2, mouse
EC 2.7.1.1
Protein Serine-Threonine Kinases
EC 2.7.11.1
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.
Langues
eng
Sous-ensembles de citation
IM
Pagination
193-204Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NIGMS NIH HHS
ID : R01 GM084459
Pays : United States
Organisme : NIH HHS
ID : S10 OD012304
Pays : United States
Commentaires et corrections
Type : ErratumIn
Références
Durgeau, A., Virk, Y., Corgnac, S. & Mami-Chouaib, F. Recent advances in targeting CD8 T-cell immunity for more effective cancer immunotherapy. Front. Immunol. 9, 14 (2018).
pubmed: 29403496
pmcid: 5786548
doi: 10.3389/fimmu.2018.00014
Geltink, R. I. K., Kyle, R. L. & Pearce, E. L. Unraveling the complex interplay between T cell metabolism and function. Annu. Rev. Immunol. 36, 461–488 (2018).
pubmed: 29677474
doi: 10.1146/annurev-immunol-042617-053019
Lim, A. R., Rathmell, W. K. & Rathmell, J. C. The tumor microenvironment as a metabolic barrier to effector T cells and immunotherapy. Elife 9, e55185 (2020).
pubmed: 32367803
pmcid: 7200151
doi: 10.7554/eLife.55185
Almeida, L., Lochner, M., Berod, L. & Sparwasser, T. Metabolic pathways in T cell activation and lineage differentiation. Semin. Immunol. 28, 514–524 (2016).
pubmed: 27825556
doi: 10.1016/j.smim.2016.10.009
Chang, C.-H. et al. Posttranscriptional control of T cell effector function by aerobic glycolysis. Cell 153, 1239–1251 (2013).
pubmed: 23746840
pmcid: 3804311
doi: 10.1016/j.cell.2013.05.016
Buck, M. D., Sowell, R. T., Kaech, S. M. & Pearce, E. L. Metabolic instruction of immunity. Cell 169, 570–586 (2017).
pubmed: 28475890
pmcid: 5648021
doi: 10.1016/j.cell.2017.04.004
Rivadeneira, D. B. & Delgoffe, G. M. Antitumor T-cell reconditioning: improving metabolic fitness for optimal cancer immunotherapy. Clin. Cancer Res. 24, 2473–2481 (2018).
pubmed: 29386217
pmcid: 5984673
doi: 10.1158/1078-0432.CCR-17-0894
Li, X. et al. Navigating metabolic pathways to enhance antitumour immunity and immunotherapy. Nat. Rev. Clin. Oncol. 16, 425–441 (2019).
pubmed: 30914826
doi: 10.1038/s41571-019-0203-7
Hashimoto, M. et al. CD8 T cell exhaustion in chronic infection and cancer: opportunities for interventions. Annu. Rev. Med. 69, 301–318 (2018).
pubmed: 29414259
doi: 10.1146/annurev-med-012017-043208
McLane, L. M., Abdel-Hakeem, M. S. & Wherry, E. J. CD8 T cell exhaustion during chronic viral infection and cancer. Annu. Rev. Immunol. 37, 457–495 (2019).
pubmed: 30676822
doi: 10.1146/annurev-immunol-041015-055318
Patsoukis, N. et al. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation. Nat. Commun. 6, 6692 (2015).
pubmed: 25809635
doi: 10.1038/ncomms7692
Rashida Gnanaprakasam, J. N., Wu, R. & Wang, R. Metabolic reprogramming in modulating T cell reactive oxygen species generation and antioxidant capacity. Front. Immunol. 9, 1075 (2018).
pubmed: 29868027
pmcid: 5964129
doi: 10.3389/fimmu.2018.01075
Ronquist, G. & Theodorsson, E. Inherited, non-spherocytic haemolysis due to deficiency of glucose-6-phosphate dehydrogenase. Scand. J. Clin. Lab. Invest. 67, 105–111 (2007).
pubmed: 17365988
doi: 10.1080/00365510601047910
Stanton, R. C. Glucose-6-phosphate dehydrogenase, NADPH, and cell survival. IUBMB Life 64, 362–369 (2012).
pubmed: 22431005
pmcid: 3325335
doi: 10.1002/iub.1017
Ho, H.-Y., Cheng, M.-L. & Chiu, D. T. Glucose-6-phosphate dehydrogenase—from oxidative stress to cellular functions and degenerative diseases. Redox Rep. 12, 109–118 (2007).
pubmed: 17623517
doi: 10.1179/135100007X200209
Yang, H.-C. et al. The redox role of G6PD in cell growth, cell death, and cancer. Cells 8, 1055 (2019).
pmcid: 6770671
doi: 10.3390/cells8091055
Yang, K. & Chi, H. mTOR and metabolic pathways in T cell quiescence and functional activation. Semin. Immunol. 24, 421–428 (2012).
pubmed: 23375549
doi: 10.1016/j.smim.2012.12.004
Maciver, N. J., Michalek, R. D. & Rathmell, J. C. Metabolic regulation of T lymphocytes. Annu. Rev. Immunol. 31, 259–283 (2013).
pubmed: 23298210
pmcid: 3606674
doi: 10.1146/annurev-immunol-032712-095956
Saravia, J., Raynor, J. L., Chapman, N. M., Lim, S. A. & Chi, H. Signaling networks in immunometabolism. Cell Res. 30, 328–342 (2020).
pubmed: 32203134
pmcid: 7118125
doi: 10.1038/s41422-020-0301-1
Shyer, J. A., Flavell, R. A. & Bailis, W. Metabolic signaling in T cells. Cell Res. 30, 649–659 (2020).
pubmed: 32709897
pmcid: 7395146
doi: 10.1038/s41422-020-0379-5
Sun, S.-C. The non-canonical NF-κB pathway in immunity and inflammation. Nat. Rev. Immunol. 17, 545–558 (2017).
pubmed: 28580957
pmcid: 5753586
doi: 10.1038/nri.2017.52
Dejardin, E. The alternative NF-κB pathway from biochemistry to biology: pitfalls and promises for future drug development. Biochem. Pharmacol. 72, 1161–1179 (2006).
pubmed: 16970925
doi: 10.1016/j.bcp.2006.08.007
Li, Y. et al. Cell intrinsic role of NF-κB-inducing kinase in regulating T cell-mediated immune and autoimmune responses. Sci. Rep. 6, 22115 (2016).
pubmed: 26912039
pmcid: 4766435
doi: 10.1038/srep22115
Wang, J., Saffold, S., Cao, X., Krauss, J. & Chen, W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161, 5516–5524 (1998).
pubmed: 9820528
doi: 10.4049/jimmunol.161.10.5516
Ahn, E. et al. Role of PD-1 during effector CD8 T cell differentiation. Proc. Natl Acad. Sci. USA 115, 4749–4754 (2018).
pubmed: 29654146
pmcid: 5939075
doi: 10.1073/pnas.1718217115
Sasaki, Y. et al. NIK overexpression amplifies, whereas ablation of its TRAF3-binding domain replaces BAFF:BAFF-R-mediated survival signals in B cells. Proc. Natl Acad. Sci. USA 105, 10883–10888 (2008).
pubmed: 18663224
pmcid: 2504772
doi: 10.1073/pnas.0805186105
Overwijk, W. W. et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8
pubmed: 12925674
pmcid: 2194177
doi: 10.1084/jem.20030590
Pearce, E. L., Poffenberger, M. C., Chang, C.-H. & Jones, R. G. Fueling immunity: insights into metabolism and lymphocyte function. Science 342, 1242454 (2013).
pubmed: 24115444
pmcid: 4486656
doi: 10.1126/science.1242454
Mizushima, N. Autophagy: process and function. Genes Dev. 21, 2861–2873 (2007).
pubmed: 18006683
doi: 10.1101/gad.1599207
Kaur, J. & Debnath, J. Autophagy at the crossroads of catabolism and anabolism. Nat. Rev. Mol. Cell Biol. 16, 461–472 (2015).
pubmed: 26177004
doi: 10.1038/nrm4024
Lamark, T., Svenning, S. & Johansen, T. Regulation of selective autophagy: the p62/SQSTM1 paradigm. Essays Biochem. 61, 609–624 (2017).
pubmed: 29233872
doi: 10.1042/EBC20170035
Mehta, M. M. et al. Hexokinase 2 is dispensable for T cell-dependent immunity. Cancer Metab. 6, 10 (2018).
pubmed: 30140438
pmcid: 6098591
doi: 10.1186/s40170-018-0184-5
Murray, S. E. et al. NF-κB–inducing kinase plays an essential T cell–intrinsic role in graft-versus-host disease and lethal autoimmunity in mice. J. Clin. Invest. 121, 4775–4786 (2011).
pubmed: 22045568
pmcid: 3223068
doi: 10.1172/JCI44943
Bollyky, P. L. et al. CD44 costimulation promotes FoxP3
pubmed: 19635906
doi: 10.4049/jimmunol.0900191
Tucker, E. et al. A novel mutation in the Nfkb2 gene generates an NF-κB2 ‘super repressor’. J. Immunol. 179, 7514–7522 (2007).
pubmed: 18025196
doi: 10.4049/jimmunol.179.11.7514
Yu, J. et al. T cell-intrinsic function of the noncanonical NF-κB pathway in the regulation of GM-CSF expression and experimental autoimmune encephalomyelitis pathogenesis. J. Immunol. 193, 422–430 (2014).
pubmed: 24899500
doi: 10.4049/jimmunol.1303237
Filomeni, G., De Zio, D. & Cecconi, F. Oxidative stress and autophagy: the clash between damage and metabolic needs. Cell Death Differ. 22, 377–388 (2015).
pubmed: 25257172
doi: 10.1038/cdd.2014.150
Kamat, J. P. & Devasagayam, T. P. Nicotinamide (vitamin B
pubmed: 10658823
doi: 10.1179/135100099101534882
Choi, H. J., Jang, S.-Y. & Hwang, E. S. High-dose nicotinamide suppresses ROS generation and augments population expansion during CD8
pubmed: 26442863
pmcid: 4625074
doi: 10.14348/molcells.2015.0168
Pretsch, W., Charles, D. J. & Merkle, S. X-linked glucose-6-phosphate dehydrogenase deficiency in Mus musculus. Biochem. Genet. 26, 89–103 (1988).
pubmed: 3377761
doi: 10.1007/BF00555491
Ham, M. et al. Glucose-6-phosphate dehydrogenase deficiency improves insulin resistance with reduced adipose tissue inflammation in obesity. Diabetes 65, 2624–2638 (2016).
pubmed: 27284106
doi: 10.2337/db16-0060
Pauken, K. E. et al. Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade. Science 354, 1160–1165 (2016).
pubmed: 27789795
pmcid: 5484795
doi: 10.1126/science.aaf2807
Wei, S. C. et al. Distinct cellular mechanisms underlie anti-CTLA-4 and anti-PD-1 checkpoint blockade. Cell 170, 1120–1133.e17 (2017).
pubmed: 28803728
pmcid: 5591072
doi: 10.1016/j.cell.2017.07.024
Varanasi, S. K., Jaggi, U., Hay, N. & Rouse, B. T. Hexokinase II may be dispensable for CD4 T cell responses against a virus infection. PLoS ONE 13, e0191533 (2018).
pubmed: 29352298
pmcid: 5774810
doi: 10.1371/journal.pone.0191533
Brightbill, H. D. et al. Conditional deletion of NF-κB-inducing kinase (NIK) in adult mice disrupts mature B cell survival and activation. J. Immunol. 195, 953–964 (2015).
pubmed: 26116508
doi: 10.4049/jimmunol.1401514
Gershon, T. R. et al. Hexokinase-2-mediated aerobic glycolysis is integral to cerebellar neurogenesis and pathogenesis of medulloblastoma. Cancer Metab. 1, 2 (2013).
pubmed: 24280485
pmcid: 3782751
doi: 10.1186/2049-3002-1-2
Zhou, X. et al. The deubiquitinase Otub1 controls the activation of CD8
pubmed: 31182807
pmcid: 6588407
doi: 10.1038/s41590-019-0405-2
Xiao, G., Harhaj, E. W. & Sun, S. C. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7, 401–409 (2001).
pubmed: 11239468
doi: 10.1016/S1097-2765(01)00187-3
Ouyang, C. et al. Transforming growth factor (TGF)-β-activated kinase 1 (TAK1) activation requires phosphorylation of serine 412 by protein kinase A catalytic subunit α (PKACα) and X-linked protein kinase (PRKX). J. Biol. Chem. 289, 24226–24237 (2014).
pubmed: 25028512
pmcid: 4148853
doi: 10.1074/jbc.M114.559963